STOCK TITAN

Provention Bio to Report First Quarter 2021 Financial Results on May 6, 2021

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences earnings

Rhea-AI Summary

Provention Bio, Inc. (Nasdaq: PRVB) will release its first quarter 2021 financial results on May 6, 2021, before U.S. markets open. Following the earnings announcement, a conference call will take place at 8:00 am E.T. to discuss the results and provide corporate updates. The company is focused on developing therapies for immune-mediated diseases, with its lead candidate, teplizumab, having a Biologics License Application filed with the FDA to delay clinical type 1 diabetes progression in at-risk individuals.

Loading...
Loading translation...

Positive

  • Biologics License Application for teplizumab filed with the FDA.
  • Focus on developing therapies for immune-mediated diseases.

Negative

  • None.
Argus Session date unavailable
-2.84% session move Open Argus
Details

News Market Reaction – PRVB

The recorded move for PRVB in the trading session of this news was -2.84%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

RED BANK, N.J., April 29, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its first quarter 2021 financial results on Thursday, May 6, 2021, before the opening of the U.S. financial markets. Subsequently, at 8:00 am E.T., the company will host a conference call to discuss its financial results and provide a corporate update.

To access the call, please dial 1-877-870-4263 (domestic) or 1-412-317-0790 (international) ten minutes prior to the start time and ask to be connected to the "Provention Bio Call." An audio webcast will also be available on the "Events and Webcasts" page of the Investors section of the Company's website, www.proventionbio.com. An archived webcast will be available on the Company's website approximately two hours after the conference call.

About Provention Bio, Inc.:

Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Biologics License Application (BLA) for teplizumab, its lead investigational drug candidate, for the delay of progression to clinical type 1 diabetes in at-risk individuals, has been filed by the U.S. Food and Drug Administration (FDA). The Company's pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.

Internet Posting of Information:

Provention Bio, Inc. uses its website, www.proventionbio.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the Company's website in the "News" section. Accordingly, investors should monitor this portion of the Company's website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

Investor Contacts: 
Robert Doody, VP of Investor Relations 
rdoody@proventionbio.com 
484-639-7235

Sam Martin, Argot Partners
sam@argotpartners.com  
212-600-1902

Media Contact:
Lori Rosen, LDR Communications 
lori@ldrcommunications.com 
917-553-6808

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/provention-bio-to-report-first-quarter-2021-financial-results-on-may-6-2021-301280603.html

SOURCE Provention Bio, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Provention Bio report its first quarter 2021 financial results?

Provention Bio will report its first quarter 2021 financial results on May 6, 2021.

What time will the conference call for Provention Bio's financial results take place?

The conference call will take place at 8:00 am E.T. on May 6, 2021.

What is Provention Bio's lead investigational drug candidate?

Provention Bio's lead investigational drug candidate is teplizumab.

What disease is teplizumab aimed to delay the progression of?

Teplizumab is aimed at delaying the progression to clinical type 1 diabetes in at-risk individuals.

Where can I access Provention Bio's conference call?

You can access Provention Bio's conference call by dialing 1-877-870-4263 or through the audio webcast on their website.

Keep reading